Rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
Sint Maartenskliniek
Eligibility
Inclusion criteria
Inclusion criteria: Rheumatoid arthritis (either 2010 ACR/EULAR RA criteria and/or 1987 ACR RA criteria and/or clinical diagnosis of the treating rheumatologist); Treatment with at least one dose of rituximab in the year prior to the first COVID-19 vaccine dose; Expected to receive a registered COVID-19 vaccine or has received a registered COVID-19 vaccine in the last 6 months; > 16 years old and mentally competent; Ability to read and communicate in Dutch. Amendment: Expected to receive a third registered COVID-19 vaccine or has received a third registered COVID-19 vaccine.
Exclusion criteria
Exclusion criteria: Not eligible (for example allergic to one of the vaccine ingredients) or not willing to receive the COVID-19 vaccine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response against COVID-19 vaccine 2-6 weeks after last vaccine dose, measured by IgT antibody index titre against COVID-19 (IgT >= 1.1) Amendment: Response against COVID-19 vaccine 2-6 weeks after third vaccine dose, dichotomized between ‘sufficient’ and ‘insufficient’ response based on the cut-off of the specific assay used. | — |
Secondary
| Measure | Time frame |
|---|---|
| Response against COVID-19 vaccine 3-6 months after last vaccine dose, measured by IgT antibody index titre against COVID-19 (IgT >= 1.1) | — |
Contacts
Public ContactCeleste van der Togt
Sint Maartenskliniek
Outcome results
None listed